Litigation Details for Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc. (D. Del. 2017)
✉ Email this page to a colleague
Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-04-05 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 6,967,208; 9,326,945 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-09-11 | 36 | BMS asserts Orange Book- listed1 U.S. Patent Nos. 6,967,208 and 9,126,945, which generally describe …. Venue in a patent infringement action is governed solely and exclusively by the patent venue statute…court sits for non-patent issues but applies its own law for issues of substantive patent law. See In re …unique to patent law. Procedural matters generally are not considered to be unique to patent law. …historical conduct that constitutes patent infringement in a typical patent lawsuit is expressly and statutorily | External link to document | |
| 2017-04-05 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,967,208 B2; US 9,326,945 … 5 April 2017 1:17-cv-00379-LPS Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
